Innovation in pharmaceutical secondary packaging is so much more than a competitive advantage – in today’s market, it is a ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today thar it has received a Notice ...

New data reveals sponsors risk wasting billions by designing overly complex trials and repeatedly recruiting from oversaturated investigator sites Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and othersLed ...

STOCKHOLM, SE / ACCESS Newswire / July 9, 2025 / iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ.) has signed an agreement with AddSecure Smart Care Oy for the distribution of the medication ...

CHICAGO, IL / ACCESS Newswire / July 9, 2025 / Dr. Anosh Ahmed, a respected Republican figure and founder of the Anosh Supports America First Foundation, has pledged immediate aid to families affected ...

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ...

Design Sets a New 2025 Bar for Healthcare AI TAMPA, FL / ACCESS Newswire / July 8, 2025 / While healthcare AI adoption is frequently hindered by poor design, weak integration, and limited clinician ...

While more than 90% of Americans support organ donation, only 52% of North Carolina's licensed drivers are registered organ, ...

Gut Zoomer provides insights crucial in identifying the root causes of chronic disease and other conditions that impact longevity SANTA CLARA, CA / ACCESS Newswire / July 8, 2025 / Vibrant Wellness, a ...

Modus Therapeutics Holding AB (publ) (“Modus”) today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment of patients with chronic kidney ...